Elevance Health (ELV) Q3 2025 10-Q Quarterly Report
Elevance Health (ELV) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Oct 21, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Elevance Health Q3 2025 10-Q Analysis
Management Discussion & Analysis
- • Revenue $50.1B Q3 2025, up 12.0% YoY ($44.7B Q3 2024); $148.3B YTD, up 13.9% YoY ($130.2B YTD 2024)
- • Operating margin 2.6% Q3 2025 vs 3.1% Q3 2024; YTD margin 4.6% vs 5.5% YoY; Health Benefits margin down to 1.4% Q3 from 4.2% YoY
Risk Factors
- • No new or changed risk factors since 2024 Annual Report on Form 10-K
- • Regulatory risk: ongoing potential adverse impact from healthcare laws and government policy changes
Elevance Health Q3 2025 Quarterly FinancialsXBRL
Revenue
$50.7B
▲ +12.4% YoY▲ +1.9% QoQ
Net Income
$1.2B
▲ +17.0% YoY▼ -31.8% QoQ
Operating Margin
2.6%
▼ -57bp YoY▼ -232bp QoQ
Net Margin
2.3%
▲ +9bp YoY▼ -116bp QoQ
ROE
2.7%
Total Assets
$122.7B
EPS (Diluted)
$5.34
▲ +22.2% YoY▼ -30.8% QoQ
Operating Cash Flow
$1.1B
▼ -57.6% YoY▼ -44.7% QoQ
Source: XBRL data from Elevance Health Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on Elevance Health
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.